Research & Development: Page 9

  • Ben Taylor, CFO, Recursion Pharmaceuticals
    Image attribution tooltip
    Permission granted by Recursion
    Image attribution tooltip
    Q&A

    AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

    Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.

    By • Feb. 27, 2025
  • Cancer vaccine
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Cancer vaccines have stumbled, but the approach is gaining new steam

    The number of candidates in development has nearly doubled over the past 15 years.

    By Kelly Bilodeau • Feb. 26, 2025
  • digital pill Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • hands pills
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Its CEO died. The company scrapped a promising program. Now, for their 2nd act.

    Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.

    By Alexandra Pecci • Feb. 25, 2025
  • Capitol building, DC
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

    Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.

    By • Feb. 25, 2025
  • pill manufacturing
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    Merck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production

    The Young Institute Pharmaceutical Manufacturing Consortium will research and develop new production technologies.

    By Alexandra Pecci • Feb. 19, 2025
  • crispr cardio
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Biotech Spotlight

    CRISPR’s cardio catch-all drives a biotech’s broad potential

    Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.

    By Kelly Bilodeau • Feb. 18, 2025
  • 3D render using close-up of heart model covered with white, red, yellow pills
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    In the crowded cardio space, it’s David vs. Goliath for small biotechs

    What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

    By Alexandra Pecci • Feb. 11, 2025
  • sleeping dream world
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Are orexins the next golden child of neuroscience?

    An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

    By • Feb. 10, 2025
  • a tech works in a pharma lab
    Image attribution tooltip
    Permission granted by Fractyl Health
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments

    Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.

    By Amy Baxter • Feb. 10, 2025
  • dollar sign syringe
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D

    With assets under a knife and pipelines under a microscope, R&D programs are being overhauled to be more efficient and cost effective.

    By Alexandra Pecci • Feb. 5, 2025
  • Front sign of FDA building
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    What should pharma make of the FDA going dark on DEI?

    After a series of potent executive orders last week, the FDA removed draft guidance on diversity in clinical trials.

    By • Feb. 4, 2025
  • bird flu avian influenza migration
    Image attribution tooltip
    David McNew via Getty Images
    Image attribution tooltip

    Drugmakers prep for bird flu outbreak, despite continued low risk

    While the virus hasn’t made a sustained leap into humans, vaccines and treatments are coming through the pipes if it does.

    By Kelly Bilodeau • Feb. 3, 2025
  • A person holds two blue drug tablets in their left hand.
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip
    Deep Dive

    A new, non-opioid pain drug is here. Getting it to patients could be agony.

    After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?

    By Jacob Bell • Feb. 3, 2025
  • petri dish seeds
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Year in Preview

    Pharma’s forecast for 2025: Sowing seeds of a rebound

    Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation. 

    By • Jan. 31, 2025
  • donald trump signs an executive order at his desk
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Is federal funding frozen? Has it already thawed? Flip-flop leaves biopharma on edge

    NIH grants that help fund drug development were caught in the mix of confusing executive orders this week.

    By Amy Baxter • Jan. 31, 2025
  • The Vertex Pharmaceuticals building in daylight on the Boston Seaport.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal?

    Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer alternatives to expand the pain management landscape.

    By Amy Baxter • Updated Feb. 4, 2025
  • natural killer cell
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Natural killer cells, a rising alternative to CAR-T cell therapy

    These innate immune cells may provide a safer, lower-cost option in cancer and autoimmune diseases.

    By Kelly Bilodeau • Jan. 27, 2025
  • dna helix
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Gene therapies have been uneven for DMD — but these companies hope to turn the tide

    Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the belief the answer could come down to delivery.

    By • Jan. 24, 2025
  • Neuron
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    J&J is all in on tau-targeted Alzheimer’s candidates. Will the approach lead to more effective treatments?

    Anti-tau candidates haven’t crossed the regulatory threshold like their anti-amyloid counterparts, but J&J’s clinical efforts could lead in the right direction.

    By • Jan. 23, 2025
  • Kristen Fortney header
    Image attribution tooltip
    Permission granted by BioAge Labs
    Image attribution tooltip

    After an obesity stumble, BioAge reconnects with its longevity pipeline

    The company is kicking off the year with a new Novartis partnership and renewed focus on metabolic aging targets.

    By Alexandra Pecci • Jan. 22, 2025
  • sketch of a brain with colorful blobs representing left and right brain
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Innovate or perish: Industry’s evolution leaves little room for me-too approaches

    Novel drug approvals have set the stage for more breakthroughs in pharma.

    By Amy Baxter • Updated Jan. 22, 2025
  • A view of Shanghai's skyline at dusk.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Deep Dive

    ‘The bar has risen’: China’s biotech gains push US companies to adapt

    Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder.

    By Ben Fidler • Jan. 17, 2025
  • Elon Musk Capitol Hill
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking

    There’s more to pharma's regulatory story in 2025 than just the IRA.

    By • Jan. 17, 2025
  • A sign spelling Merck hangs on the side of an office building
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck is broadening its pipeline as Keytruda’s patent cliff looms

    Merck looks ahead with an array of cardiometabolic, immunology, neuroscience and ophthalmology pipelines.

    By Alexandra Pecci • Jan. 14, 2025
  • Biopharma market
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Year in Preview

    Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A?

    A series of uncertainties that kept dealmaking to a minimum last year could be reversing as pharma reloads pipelines ahead of the patent cliff explosion.

    By • Jan. 14, 2025